Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chidel, M. A.
Right arrow Articles by Becker, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chidel, M. A.
Right arrow Articles by Becker, M.

Resectable Esophageal Carcinoma: Local Control with Neoadjuvant Chemotherapy and Radiation Therapy1

Mark A. Chidel, MD, Thomas W. Rice, MD, David J. Adelstein, MD, Patrick A. Kupelian, MD, John H. Suh, MD and Mark Becker, MD

1 From the Departments of Radiation Oncology (M.A.C., P.A.K., J.H.S., M.B.), Thoracic Surgery (T.W.R.), and Hematology and Oncology (D.J.A.), Cleveland Clinic Foundation, 9500 Euclid Ave, Desk T-28, Cleveland, OH 44195. From the 1997 RSNA scientific assembly. Received September 22, 1998; revision requested November 4; revision received December 22; accepted March 8, 1999. Address reprint requests to P.A.K.



View larger version (20K):

[in a new window]
  		Figure 1. Diagram demonstrates the neoadjuvant chemotherapy and radiation therapy regimen. BID = twice daily, CDDP = cisplatin, fx = fraction, IV = intravenous, XRT = radiation therapy, 5-FU = fluorouracil.

 


View larger version (11K):

[in a new window]
  		Figure 2. Graph shows the overall survival rate for all patients.

 


View larger version (10K):

[in a new window]
  		Figure 3. Graph shows the disease-free survival rate for all patients.

 


View larger version (12K):

[in a new window]
  		Figure 4. Graph shows the distant metastatic relapse-free survival rate for each treatment modality. CMT = combined-modality therapy.

 


View larger version (13K):

[in a new window]
  		Figure 5. Graph shows the local-regional relapse-free survival rate for each treatment modality. CMT = combined-modality therapy.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1999 by the Radiological Society of North America.